+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

United States Prostate Cancer Testing Market by Biomarker Type, Application, End-user, Region, Competition Forecast & Opportunities, 2018-2028

  • PDF Icon


  • 78 Pages
  • July 2023
  • Region: United States
  • TechSci Research
  • ID: 5849432
Free Webex Call
10% Free customization
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

The United States Prostate Cancer Testing Market is expected to grow at an impressive rate during the forecast period 2024-2028. The major factors include the increasing prevalence of prostate cancer in men, increasing prostate cancer screening and testing, early diagnosis of prostate cancer, and increasing interest of the government in cancer testing and medical advancement. According to Global Cancer Observatory, in 2020, around 2,281,658 new cancer cases were reported in the United States, among which 209,512 cases reported were of prostate cancer. Additionally, increasing awareness among the public for early prostate diagnosis and detection is further expected to drive the growth of United States prostate cancer testing market.

The prostate gland's aberrant cells multiply and uncontrollably enlarge in men with prostate cancer. The tenth leading cause of mortality overall and the sixth major cause of death in men is prostate cancer. According to Statista, the United States leads among all countries across the globe in terms of spending on research and development, with expenditures exceeding USD679.4 billion.

Rising prevalence of prostate cancer

In United States, prostate cancer is the most prevalent cancer in men. This is diagnosed in about 6 out of 10 men who are 65 years old and rare in men under 40 years. Prostate cancer is the second most common cancer among American males, after lung cancer. For instance, in the United States, it was predicted that about 268,490 new cases of prostate cancer were reported in 2022, up from 192,280 new cases in 2009. Moreover, it was estimated that in 2022 around 34,500 men will die of prostate cancer in the U.S.

Growing Geriatric Population

Globally, cancer is the leading cause of death. According to the American Society of Clinical Oncologists, prostate cancer is more than twice as likely in people over 70 years as compared to younger people. This is due to genetic disorders, unhealthy lifestyles, environment, radiation, physical carcinogens, chemical carcinogens as well as biological carcinogens. The need to develop testing procedures for cancer is expected to support the growth of the US prostate cancer testing market.

Government Initiatives Related to Prostate Cancer

The government provides funding for developing new technologies to enhance the testing of prostate cancer positively. For instance, the National Cancer Institute initiated Prostate Specialized Programs of Research Excellence (SPORE), -a program designed to convert scientific findings into clinical settings-based outcomes. The institute also facilitates the development of new technologies and studies to gain a better understanding of monitoring, prevention, diagnosis, and treatment. Such initiatives are expected to drive the growth of the United States Prostate Cancer Testing Market.

Technological Development

The techniques like prostate-specific antigen (PSA) testing, which have developed over the years that confirm tumor progression and proliferation, have created new prospects for the growth of prostate cancer testing over the years. Moreover, prostate cancer testing is essential in precision medicine because it assures the safe and successful use of testing methods. Additionally, most of the companies in the U.S. prostate cancer testing market provide biomarker tests that are urine, blood, and tissue-based, as well as testing services. This, in turn, shows an impressive rate of growth in the United States prostate cancer market.

Recent Developments

According to the Journal of the National Cancer Institute, in September 2022, a company, namely Veracyte, Inc., announced the publishing of data to demonstrate that the company's decipher prostate genomic classifier may help identify African American men with early, localized prostate cancer who are most likely to harbor more aggressive disease.

Additionally, in June 2021, Thermo Fisher Scientific announced submissions open for the Oncomine Clinical Research Grant program to support clinical research projects in oncology. Due to this grant, the funding for high-quality molecular profiling studies focuses on the impact of immune-based treatments for cancer patients.

Market Segmentation

United States Prostate Cancer Testing Market can be segmented by biomarker type, application, end-user, region, and competitive landscape. Based on biomarker type, the market can be segmented into pre-biopsy/post-negative biopsy testing, initial evaluation: prostate-specific antigen (Total PSA, Free PSA), and post-biopsy tissue testing. Based on application, the market can be segmented into diagnostics biomarkers and prognostics biomarkers. In terms of end users, the market can be segmented into cancer research institutes, diagnostic laboratories, hospitals and clinics, ambulatory surgical centers (ASCs), and others.

Market Players

F. Hoffmann-La Roche Ltd (Foundation Medicine, Inc.), Siemens Healthcare GmbH, OPKO Health, Inc. (GenPath), Myriad Genetics Inc., NeoGenomics Laboratories, Danaher. (Beckman Coulter, Inc.), Agilent Technologies, Inc., Abcam plc., Bio-Techne. (ExoDx), H.U. Group Holdings, Inc. (Fujeribio), etc., are some of the leading companies operating in the market.

Report Scope

In this report, United States Prostate Cancer Testing Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

United States Prostate Cancer Testing Market, By Biomarker Type:

  • Pre-Biopsy/Post-Negative Biopsy Testing
  • Initial Evaluation: Prostate-Specific Antigen (Total PSA, Free PSA)
  • Post-Biopsy Tissue Testing

United States Prostate Cancer Testing Market, By Application:

  • Diagnostics Biomarkers
  • Prognostics Biomarkers

United States Prostate Cancer Testing Market, By End User:

  • Cancer Research Institutes
  • Diagnostic Laboratories
  • Hospitals and Clinics
  • Ambulatory Surgical Centers (ASCs)
  • Others

United States Prostate Cancer Testing Market, By Region:

  • Northeast
  • Midwest
  • South
  • West

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in United States Prostate Cancer Testing Market

Available Customizations

With the given market data, the analyst offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. United States Prostate Cancer Testing Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Biomarker Type (Pre-Biopsy/Post-Negative Biopsy Testing, Initial Evaluation: Prostate-Specific Antigen (Total PSA, Free PSA), Post-Biopsy Tissue Testing)
5.2.2. By Application (Diagnostics Biomarkers, Prognostics Biomarkers)
5.2.3. By End-user (Cancer Research Institutes, Diagnostic Laboratories, Hospitals and Clinics, Ambulatory Surgical Center (ASCs), and Others)
5.2.4. By Region (Northeast Region, Midwest Region, South Region, West Region)
5.2.5. By Company (2022)
5.3. Market Map
5.3.1. By Biomarker Type
5.3.2. By Application
5.3.3. By End-user
5.3.4. By Region
6. Northeast United States Prostate Cancer Testing Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Biomarker Type
6.2.2. By Application
6.2.3. By End-user
7. Midwest United States Prostate Cancer Testing Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Biomarker Type
7.2.2. By Application
7.2.3. By End-user
8. South United States Prostate Cancer Testing Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Biomarker Type
8.2.2. By Application
8.2.3. By End-user
9. West United States Prostate Cancer Testing Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Biomarker Type
9.2.2. By Application
9.2.3. By End-user
10. Market Dynamics
10.1. Drivers
10.1.1. Rising prevalence of prostate cancer
10.1.2. Growing geriatric population
10.1.3. Government Initiatives related to Prostate Cancer
10.1.4. Technological Advancement
10.1.5. Recent Development
10.2. Challenges
10.2.1. High Probability of False Positives during Prostate Cancer Testing
11. Market Trends & Developments12. United States Economic Profile
13. Competitive Landscape
13.1. Business Overview
13.2. Product Offerings
13.3. Recent Developments
13.4. Financials (As Reported)
13.5. Key Personnel
13.5.1. F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.).
13.5.2. Siemens Healthcare GmbH
13.5.3. OPKO Health, Inc. (GenPath)
13.5.4. Myriad Genetics Inc.
13.5.5. NeoGenomics Laboratories
13.5.6. Danaher. (Beckman Coulter, Inc.)
13.5.7. Agilent Technologies, Inc.
13.5.8. Abcam plc.
13.5.9. Bio-Techne. (ExoDx)
13.5.10. H.U. Group Holdings, Inc. (Fujeribio)
14. Strategic Recommendations

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.).
  • Siemens Healthcare GmbH
  • OPKO Health, Inc. (GenPath)
  • Myriad Genetics Inc.
  • NeoGenomics Laboratories
  • Danaher. (Beckman Coulter, Inc.)
  • Agilent Technologies, Inc.
  • Abcam PLC.
  • Bio-Techne. (ExoDx)
  • H.U. Group Holdings, Inc. (Fujeribio)